Joint Accreditation Statement
CME expiration date: Sept 9, 2025
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA-4008290-0000-24-006-H01-P)
Type of Activity: Knowledge
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Method of Participation and Request for Credit
To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
There is no fee to participate.
Disclosures
Projects In Knowledge® adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests)*. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Michele Rubin, MSN, APRN, CNS-BC, CGRN, has no relevant financial relationships to disclose.
Lisa Cimakasky, PhD, (medical writer), has no relevant financial relationships to disclose.
Peer Reviewer has no relevant financial relationships to disclose.
Vandana G. Abramson, MD (IPE Committee) has no relevant financial relationships to disclose.
Jason D. Astrin, DMSc, MBA, PA-C, DFAAPA (IPE Committee) has no relevant financial relationships to disclose.
Ella Balasa, Patient Advocate (IPE Committee), has been a content creator for Health Union; and has been on the patient advisory board for Genentech, A Member of the Roche Group, Health Union, Medidata, Parexel, and ZS Consulting.
James D. Bowen, MD (IPE Committee), has received honoraria from Biogen, EMD Serono, Inc., Genentech, and Novartis; has received consulting fees from Biogen, Celgene, EMD Serono, Genentech, a Member of the Roche Group, and Novartis Pharmaceuticals Corporation; has conducted contracted research for Alexion Pharmaceuticals, Inc, Alkermes, Biogen, Celgene Corporation, Genentech, a Member of the Roche Group, Genzyme, Novartis Pharmaceuticals Corporation, and TG Therapeutics, Inc; and has ownership interest in Amgen Inc.
Anita Roy Desai, MD, FAAP (IPE Committee), has no relevant financial relationships to disclose.
Veronica Esquible, PharmD (IPE Committee), has no relevant financial relationships to disclose.
Bradley Monk, MD, FACOG, FACS (IPE Committee), has received consulting fees from AbbVie, Inc, Advaxis, Inc., Agenus Inc., Amgen Inc., Aravive, Inc., Asymmetric Therapeutics, Boston Biomedical, Chemocare, ChemoID, Circulogene, Conjupro Biotherapeutics Inc, Eisai Co., Ltd, Geistlich Pharma North America, Inc., Genmab/Seattle Genetics, GOG Foundation, Immunomedics, Inc., ImmunoGen, Inc., Incyte Corporation, Laekna Healthcare Private Limited, Mateon Therapeutics, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Mersana Therapeutics, Inc., Myriad Genetics, Nucana, OncoMed Pharmaceuticals, OncoQuest Inc., OncoSec Medical Inc, Perthera Inc., Pfizer Inc., Precision Oncology, Puma Biotechnology Inc, Regeneron Pharmaceuticals, Samumed, LLC, Takeda Pharmaceutical Company, Ltd, VBL Therapeutics, and Vigeo Therapeutics; and has been a Speaker/Consultant for AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche Ltd/ Genentech, A Member of the Roche Group, Janssen Pharmaceuticals/Johnson & Johnson, Inc., and Tesaro, Inc/GlaxoSmithKline.
Brant Oliver, PhD, MS, MPH, APRN-BC (IPE Committee), has conducted contracted research for Biogen and EMD Serono.
Ilon S. Rincon Portas, MD (IPE Committee), has no relevant financial relationships to disclose.
Katherine Sibler, MSN, WHNP-BC (IPE Committee), has no relevant financial relationships to disclose.
Projects In Knowledge staff members have no relevant financial relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
*An ineligible company (commercial interest) is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used, on patients.
Off-Label Drug Statement: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
